CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
50.17
-1.83 (-3.52%)
At close: Feb 4, 2026, 4:00 PM EST
50.16
-0.01 (-0.02%)
After-hours: Feb 4, 2026, 5:31 PM EST
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$97,550
Profits / Employee
-$1,242,486
Market Cap
4.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 654 |
| Corcept Therapeutics | 500 |
| Amicus Therapeutics | 499 |
| Crinetics Pharmaceuticals | 437 |
| TG Therapeutics | 374 |
| Immunovant | 362 |
| Apogee Therapeutics | 196 |
| Scholar Rock Holding | 128 |
CRSP News
- 21 days ago - Crispr Therapeutics: Patience And Opportunity Through Volatility - Seeking Alpha
- 23 days ago - CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key - Seeking Alpha
- 5 weeks ago - Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
- 6 weeks ago - CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer - Benzinga
- 6 weeks ago - CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies - GlobeNewsWire